Journal
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY
Volume 14, Issue -, Pages -Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/17562848211064080
Keywords
adherence; antibiotics; bismuth; culture; global antimicrobial resistance; Helicobacter pylori; molecular susceptibility testing; proton pump inhibitors; test-of-cure; therapy; vonoprazan
Categories
Funding
- Office of Research and Development Medical Research Service Department of Veterans Affairs, Public Health Service grant, Texas Medical Center Digestive Diseases Center [DK56338]
Ask authors/readers for more resources
The diagnosis and therapy of Helicobacter pylori infection have evolved significantly with a focus on optimizing treatments to achieve high cure rates and the use of susceptibility profiling. Ioncreased antimicrobial resistance has led to restriction of certain antibiotics to susceptibility-based therapies, and the availability of PCR testing has allowed for rapid detection of resistance. Current recommendations include using only highly effective therapies locally and performing test-of-cure to inform the community about effective treatments.
The diagnosis and therapy of Helicobacter pylori infection have undergone major changes based on the use the principles of antimicrobial stewardship and increased availability of susceptibility profiling. H. pylori gastritis now recognized as an infectious disease, as such there is no placebo response allowing outcome to be assessed in relation to the theoretically obtainable cure rate of 100%. The recent recognition of H. pylori as an infectious disease has changed the focus to therapies optimized to reliably achieve high cure rates. Increasing antimicrobial resistance has also led to restriction of clarithromycin, levofloxacin, or metronidazole to susceptibility-based therapies. Covid-19 resulted in the almost universal availability of polymerase chain reaction testing in hospitals which can be repurposed to utilize readily available kits to provide rapid and inexpensive detection of clarithromycin resistance. In the United States, major diagnostic laboratories now offer H. pylori culture and susceptibility testing and American Molecular Laboratories offers next-generation sequencing susceptibility profiling of gastric biopsies or stools for the six commonly used antibiotics without need for endoscopy. Current treatment recommendations include (a) only use therapies that are reliably highly effective locally, (b) always perform a test-of-cure, and (c) use that data to confirm local effectiveness and share the results to inform the community regarding which therapies are effective and which are not. Empiric therapy should be restricted to those proven highly effective locally. The most common choices are 14-day bismuth quadruple therapy and rifabutin triple therapy. Prior guidelines and treatment recommendations should only be used if proven locally highly effective.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available